Indeks Rilis Pers English

Hankook's Ventus Delivers Unwavering Performance Throughout WRC FORUM8 Rally Japan's Ever-Changing Conditions
PR Newswire
Senin, 1 Jun

Hankook's Ventus Delivers Unwavering Performance Throughout WRC FORUM8 Rally Japan's Ever-Changing Conditions

UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities
PR Newswire
Senin, 1 Jun

UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities

BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations
PR Newswire
Senin, 1 Jun

BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations

Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officer
PR Newswire
Senin, 1 Jun

Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officer

Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers
PR Newswire
Senin, 1 Jun

Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers

Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibration
PR Newswire
Senin, 1 Jun

Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibration

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
PR Newswire
Senin, 1 Jun

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
PR Newswire
Senin, 1 Jun

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
PR Newswire
Senin, 1 Jun

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
PR Newswire
Senin, 1 Jun

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D
PR Newswire
Senin, 1 Jun

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026
PR Newswire
Senin, 1 Jun

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
PR Newswire
Senin, 1 Jun

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
PR Newswire
Senin, 1 Jun

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
PR Newswire
Senin, 1 Jun

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
PR Newswire
Senin, 1 Jun

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
PR Newswire
Senin, 1 Jun

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
PR Newswire
Senin, 1 Jun

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
PR Newswire
Minggu, 31 Mei

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF
PR Newswire
Minggu, 31 Mei

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF